Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $839.85 million. The enterprise value is $556.07 million.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 51.49 million shares outstanding. The number of shares has increased by 5.45% in one year.
| Current Share Class | 51.49M |
| Shares Outstanding | 51.49M |
| Shares Change (YoY) | +5.45% |
| Shares Change (QoQ) | +2.21% |
| Owned by Insiders (%) | 6.48% |
| Owned by Institutions (%) | 50.27% |
| Float | 24.13M |
Valuation Ratios
The trailing PE ratio is 7.92 and the forward PE ratio is 6.46.
| PE Ratio | 7.92 |
| Forward PE | 6.46 |
| PS Ratio | 7.82 |
| Forward PS | 7.23 |
| PB Ratio | 2.81 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | 3.52 |
| P/OCF Ratio | 3.52 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 5.25 |
| EV / Sales | 5.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.33 |
Financial Position
The company has a current ratio of 10.93, with a Debt / Equity ratio of 0.14.
| Current Ratio | 10.93 |
| Quick Ratio | 10.73 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.18 |
| Interest Coverage | -1.46 |
Financial Efficiency
Return on equity (ROE) is 44.85% and return on invested capital (ROIC) is -3.66%.
| Return on Equity (ROE) | 44.85% |
| Return on Assets (ROA) | -0.54% |
| Return on Invested Capital (ROIC) | -3.66% |
| Return on Capital Employed (ROCE) | -0.81% |
| Weighted Average Cost of Capital (WACC) | 5.14% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | $1.18M |
| Employee Count | 90 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $23.35 million in taxes.
| Income Tax | 23.35M |
| Effective Tax Rate | 18.07% |
Stock Price Statistics
The stock price has increased by +75.19% in the last 52 weeks. The beta is 0.17, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +75.19% |
| 50-Day Moving Average | 16.27 |
| 200-Day Moving Average | 15.79 |
| Relative Strength Index (RSI) | 50.80 |
| Average Volume (20 Days) | 459,655 |
Short Selling Information
The latest short interest is 5.26 million, so 10.22% of the outstanding shares have been sold short.
| Short Interest | 5.26M |
| Short Previous Month | 5.15M |
| Short % of Shares Out | 10.22% |
| Short % of Float | 21.81% |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, TBPH had revenue of $107.46 million and earned $105.90 million in profits. Earnings per share was $2.06.
| Revenue | 107.46M |
| Gross Profit | 70.05M |
| Operating Income | -3.60M |
| Pretax Income | 129.25M |
| Net Income | 105.90M |
| EBITDA | -1.98M |
| EBIT | -3.60M |
| Earnings Per Share (EPS) | $2.06 |
Full Income StatementBalance Sheet
The company has $315.36 million in cash and $42.70 million in debt, with a net cash position of $283.78 million or $5.51 per share.
| Cash & Cash Equivalents | 315.36M |
| Total Debt | 42.70M |
| Net Cash | 283.78M |
| Net Cash Per Share | $5.51 |
| Equity (Book Value) | 296.72M |
| Book Value Per Share | 5.81 |
| Working Capital | 380.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $238.54 million and capital expenditures -$42,000, giving a free cash flow of $238.50 million.
| Operating Cash Flow | 238.54M |
| Capital Expenditures | -42,000 |
| Depreciation & Amortization | 1.63M |
| Net Borrowing | n/a |
| Free Cash Flow | 238.50M |
| FCF Per Share | $4.63 |
Full Cash Flow StatementMargins
Gross margin is 65.18%, with operating and profit margins of -3.35% and 98.54%.
| Gross Margin | 65.18% |
| Operating Margin | -3.35% |
| Pretax Margin | 120.27% |
| Profit Margin | 98.54% |
| EBITDA Margin | -1.84% |
| EBIT Margin | -3.35% |
| FCF Margin | 221.93% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.45% |
| Shareholder Yield | -5.45% |
| Earnings Yield | 12.61% |
| FCF Yield | 28.40% |
Analyst Forecast
The average price target for TBPH is $18.40, which is 12.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.40 |
| Price Target Difference | 12.81% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 25.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of 0.59 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.59 |
| Piotroski F-Score | 6 |
